Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes

BACKGROUND: In a previous pooled analysis of 12 double-blind clinical studies that included data on 6,139 patients with type 2 diabetes, treatment with sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, was shown to be generally well tolerated compared with treatment with control agents. As cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Williams-Herman, Debora, Engel, Samuel S, Round, Elizabeth, Johnson, Jeremy, Golm, Gregory T, Guo, Hua, Musser, Bret J, Davies, Michael J, Kaufman, Keith D, Goldstein, Barry J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3161395/
https://www.ncbi.nlm.nih.gov/pubmed/20412573
http://dx.doi.org/10.1186/1472-6823-10-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3161395/
https://www.ncbi.nlm.nih.gov/pubmed/20412573
http://dx.doi.org/10.1186/1472-6823-10-7

Ejemplares similares